Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma

• Status: Recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Hodgkin's Lymphoma (HL) is a neoplasm that affects the lymph nodes and the lymphatic system. In Mexico, HL is the seventh most incident cancer and the ninth with the highest mortality. It is characterized by the presence of Reed-Sternberg (HRS) cells derived from B cells of the germinal center. They harbor mutations that activate the NF-κB pathway, favoring cell survival and their reprogram. Currently, the available therapeutic options are chemotherapy and radiotherapy, achieving cure rates of 75% in patients in advanced stages, in which 70% of these are found at the time of diagnosis. The investigators proposed the use of pentoxifylline (PTX) as a therapeutic option to enhance the antitumor effect generated by the treatment, since it can increases the efficacy of apoptosis, in vitro and in vivo, induced by doxorubicin, cisplatin, and adriamycin in human leukemic and cervical cancer cells, through inhibition of NF-κB by preventing phosphorylation of serine 32 of the inhibitor κB; it also decreases the expression of Bcl-2 and Bcl-XL, induces the release of cytochrome c and caspases 3, 9, and cleavage of caspase 8. The investigators evaluated the effects of PTX during the steroid window phase at induction to remission in pediatric patients with LLA of a recent diagnosis, where it was shown that the combined treatment of prednisone (PRD) with PTX achieves greater percentages of apoptosis compared to individual treatment. In addition, the effect of PTX on the expression of genes associated with apoptosis was evaluated; where it was shown that activates the intrinsic and extrinsic pathways of apoptosis. Fortilin is a protein whose serum levels increase 2.4 times more after treatment with chemotherapy or radiotherapy in patients with malignancies, so it is considered a specific and sensitive biomarker of early apoptosis in vivo. The present protocol will evaluate the enhancing effect of PTX on tumor apoptosis in combination with chemotherapeutical agents in pediatric and AYA patients with HL. Apoptosis will be measured in vivo by quantifying serum levels of fortilin and cytochrome c in participants before and after treatment by ELISA; as well as an evaluation of the clinical response based on the results of the PET-Scan, overall and event-free survival according to the Kaplan-Meier curves, and the adverse effects associated with the use of PTX according to the common terminology criteria for adverse events and causality algorithms.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guadalajara
• Collaborator: Hospital Civil de Guadalajara
• Treatments: Pentoxifylline

Criteria

Inclusion Criteria:

• Pediatric and AYA (adolescents and young adults) patients (age up to 35 years of both sexes) with newly diagnosed

• Hodgkin lymphoma regardless of clinical stage.

• Patients with the ability to swallow tablets.

• Patients who agree to enter the protocol by signing the informed consent personally or by the parent/guardian

Exclusion Criteria:

• Patients previously treated with chemotherapy and/or radiotherapy

• History of active acid peptic disease or gastrointestinal bleeding Intolerance to pentoxifylline and in general to xanthines

• Patients under treatment with anticoagulants, cimetidine, ciprofloxacin or theophylline

• Patients with severe bleeding, retinal hemorrhage or bleeding diathesis

• Serious cardiac arrhythmias (E.g. paroxysmal supraventricular tachycardia, congenital AV block, arrhythmias associated with congenital heart disease, digitalis poisoning, postoperative cardiac surgery, hypoxia, hypercapnia, electrolyte disturbances)

• Patients with hypotension

• Severe liver failure

• Moderate to severe renal insufficiency (with a glomerular filtration rate ≤ 30 mL/min)

• Patients admitted to the Intensive Care Unit at diagnosis

• Patients with treatment adherence of less than 80%

• Patients who wish to withdraw from the study or withdraw informed consent

• Patients who present grade III adverse events related to the drug under study

• Patients who become pregnant during the study